Biochemical and Biophysical Research Communications
Volume 255, Issue 2, 16 February 1999, Pages 268-273
Regular ArticleSmad6 Suppresses TGF-β-Induced Growth Inhibition in COLO-357 Pancreatic Cancer Cells and Is Overexpressed in Pancreatic Cancer
References (35)
- et al.
Cell
(1997) - et al.
Gastroenterology
(1993) - et al.
J. Biol. Chem.
(1998) - et al.
Biochem. Biophys. Res. Commun.
(1998) - et al.
Biochem. Biophys. Res. Commun.
(1998) - et al.
J. Biol. Chem.
(1996) - et al.
Cell
(1996) - et al.
Cell
(1998) - et al.
J. Cell Biol.
(1992) Ann. Rev. Biochem.
(1998)
Nature
(1997)
Proc. Natl. Acad. Sci. USA
(1997)
Nature
(1997)
Nature
(1997)
Genes Dev.
(1998)
N. Engl. J. Med.
(1992)
Oncogene
(1998)
Cited by (106)
Aberrant Signaling Pathways in Pancreatic Cancer: Opportunities for Targeted Therapeutics
2009, Handbook of Cell Signaling, Second EditionActivation of growth factor receptors in pancreatic cancer
2007, American Journal of SurgeryCitation Excerpt :The TGF-β–signaling inhibitors Smad6 and Smad7 are also markedly overexpressed in PDAC [60,61]. Transfection of the TGF-β–-responsive pancreatic cancer cell line COLO-357 with Smad6 and Smad7 resulted in abrogation of growth inhibition by TGF-β [60,61]. Recently, 2 research groups reported the establishment of Smad4 knockdown pancreatic cancer cell lines [68,69].
Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network
2022, Translational Cancer ResearchNatural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes
2021, Signal Transduction and Targeted Therapy
- 1
Current address: Praecis Pharmaceuticals, Cambridge, MA 02139.
- 2
To whom correspondence should be addressed. Division of Endocrinology, Diabetes and Metabolism, Medical Sciences I, C240, University of California, Irvine, CA 92697. Fax: 949-824-1035. E-mail:[email protected].
Copyright © 1999 Academic Press. All rights reserved.